MedPath

Efficacy and safety of combination therapy with tolvaptan and dapagliflozin in patients with acute decompensated heart failure: A randomized controled trial

Not Applicable
Recruiting
Conditions
Acute decompensated heart failure
Registration Number
JPRN-UMIN000039340
Lead Sponsor
Kansai Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with acute coronary syndrome Patients with out-of-hospital cardiac arrest No tolerability of tolvaptan or dapagliflozin Rejected study enrollment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath